New insights into diagnosis and treatment of heart muscle disease in children
Cardiomyopathies (heart muscle diseases) in children are the focus of a new scientific statement from the American Heart Association that provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities. It will be published in the American Heart Association's journal Circulation.
When a child has certain types of cardiomyopathy, their heart is not able to pump blood efficiently. Symptoms may include difficulty breathing, heart rhythm abnormalities, dizziness, swollen hands and feet or other indications.
Although rare, cardiomyopathies in children can be life threatening and often result in either a child needing a heart transplant or premature death. There are many causes of cardiomyopathies including genetic variations that affect basic heart functions, systemic diseases, such as infections, treatments for medical conditions that injure the heart and many others, some of which are not yet understood.
According to the statement:
- Nearly 40% of children who are diagnosed with cardiomyopathies that produce symptoms receive a heart transplant or die within the first two years after diagnosis.
- The percentage of children with cardiomyopathy who received a heart transplant has not declined over the past 10 years.
- Cardiomyopathy remains the leading cause of transplantation for children over one year of age.
Dr. Lipshultz is also the Chair of the Medical Advisory Board of the Children's Cardiomyopathy Foundation, which partners with the American Heart Association on funding pediatric cardiomyopathy research grants.
Source:
Journal reference:
Lipshultz, S.E. et al. (2019) Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation. doi.org/10.1161/CIR.0000000000000682.
.png)
No hay comentarios:
Publicar un comentario